Showing 1 posts of 1 posts found.
Kymab, the UK-based antibody biopharmaceutical group, announced that it has secured $100 million in funding. The company raised the funds …
Lonza and Engitix partner to develop next-generation antibody-drug conjugates
Simris Group appoints Tiffany J Vora as Strategic Advisor
Cizzle Biotechnology expands US rollout of lung cancer blood test
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide